NEW YORK, March 23 (GenomeWeb News) - DxS and BTG said today that they have signed an exclusive license to commercialize technology developed by AstraZeneca for the detection of SNPs and other gene mutations.
DxS and BTG said they had acquired "certain rights" to AstraZeneca's technology, and would market AstraZeneca's Amplification Refractory Mutation System (ARMS) within the diagnostic and research markets.
The technology will be targeted toward companies that offer genetic variation products and services, as well as companies that are already using ARMS as part of their in-house research activities, DxS and BTG said.
DxS, a genetic analysis services provider, will offer ARMS in addition to its own Scorpions genotyping system. Stephen Little, DxS CEO, called ARMS "an excellent fit with our current portfolio."